Eli Lil­ly, Boehringer In­gel­heim re­vise pro­lif­ic di­a­betes pact, fir­ing all cylin­ders for block­buster Jar­diance fran­chise

Eli Lil­ly bet big to en­list Boehringer In­gel­heim as an al­ly in es­tab­lish­ing a di­a­betes king­dom back in 2011, pay­ing €300m ($390m) to get its hands on two of the Ger­man drug­mak­er’s ex­per­i­men­tal com­pounds and more man­pow­er for two of its own drugs. With­in eight years, three of those drugs have grown up to be mar­ket­ed prod­ucts and the part­ners are re­vis­ing their co-par­ent­ing terms.

Jar­diance — the SGLT-2 in­hibitor then dubbed BI10773 — emerged as the fa­vorite child of the “mod­ern­ized” deal. Start­ing from next year, it will be the on­ly drug for which Lil­ly and Boehringer con­tin­ue to co-de­vel­op and com­mer­cial­ize. Lil­ly will take pri­ma­ry re­spon­si­bil­i­ty for its in­sulin ana­log Basaglar, while Boehringer will lead projects re­lat­ed to Tra­jen­ta, its DPP-4 drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER